 Eva Nozik
Concepts (383)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Superoxide Dismutase | 22 | 2025 | 301 | 6.150 |
Why?
| | Hypertension, Pulmonary | 26 | 2026 | 1980 | 2.720 |
Why?
| | Acute Lung Injury | 8 | 2023 | 303 | 2.380 |
Why?
| | Hypoxia | 11 | 2026 | 1199 | 2.210 |
Why?
| | Pneumonia, Staphylococcal | 2 | 2025 | 27 | 1.630 |
Why?
| | Lung | 30 | 2026 | 4109 | 1.550 |
Why?
| | Vascular Remodeling | 8 | 2026 | 205 | 1.510 |
Why?
| | Blood Platelets | 5 | 2026 | 400 | 1.450 |
Why?
| | Hyaluronic Acid | 3 | 2025 | 208 | 1.410 |
Why?
| | Mice, Inbred C57BL | 21 | 2025 | 5992 | 1.350 |
Why?
| | Platelet Activation | 5 | 2026 | 104 | 1.330 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2024 | 2145 | 1.180 |
Why?
| | Pulmonary Artery | 14 | 2025 | 1134 | 1.180 |
Why?
| | Bleomycin | 8 | 2018 | 253 | 1.160 |
Why?
| | Pneumonia | 5 | 2022 | 631 | 1.010 |
Why?
| | Hypertrophy, Right Ventricular | 8 | 2022 | 150 | 0.950 |
Why?
| | Mice | 39 | 2026 | 18339 | 0.920 |
Why?
| | Animals | 62 | 2026 | 38058 | 0.890 |
Why?
| | Oxidation-Reduction | 6 | 2023 | 1087 | 0.870 |
Why?
| | Macrophages, Alveolar | 6 | 2024 | 368 | 0.850 |
Why?
| | Reactive Oxygen Species | 9 | 2025 | 621 | 0.840 |
Why?
| | Myocytes, Smooth Muscle | 7 | 2025 | 266 | 0.830 |
Why?
| | Lung Injury | 5 | 2021 | 237 | 0.830 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2022 | 410 | 0.810 |
Why?
| | Superoxides | 2 | 2025 | 204 | 0.800 |
Why?
| | Cell Communication | 1 | 2025 | 324 | 0.780 |
Why?
| | Macrophages | 5 | 2025 | 1511 | 0.760 |
Why?
| | Disease Models, Animal | 14 | 2026 | 4557 | 0.740 |
Why?
| | Inflammation | 10 | 2025 | 2878 | 0.720 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2017 | 28 | 0.660 |
Why?
| | Endothelial Cells | 5 | 2025 | 869 | 0.630 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 248 | 0.610 |
Why?
| | Receptor, EphA2 | 2 | 2018 | 17 | 0.600 |
Why?
| | Neutrophils | 1 | 2025 | 1134 | 0.590 |
Why?
| | Pulmonary Fibrosis | 4 | 2017 | 395 | 0.580 |
Why?
| | Endothelium, Vascular | 4 | 2018 | 965 | 0.580 |
Why?
| | Alpha-Globulins | 2 | 2018 | 19 | 0.570 |
Why?
| | Mice, Knockout | 9 | 2025 | 3121 | 0.540 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 18 | 0.540 |
Why?
| | Protective Agents | 1 | 2018 | 42 | 0.530 |
Why?
| | Liposomes | 3 | 2017 | 250 | 0.500 |
Why?
| | MicroRNAs | 2 | 2022 | 701 | 0.470 |
Why?
| | Staphylococcus aureus | 3 | 2025 | 455 | 0.460 |
Why?
| | Early Growth Response Protein 1 | 2 | 2011 | 32 | 0.440 |
Why?
| | Vasodilator Agents | 6 | 2017 | 331 | 0.420 |
Why?
| | Pulmonary Alveoli | 2 | 2021 | 383 | 0.410 |
Why?
| | Mice, Transgenic | 7 | 2025 | 2182 | 0.400 |
Why?
| | Extracellular Space | 2 | 2011 | 120 | 0.390 |
Why?
| | Signal Transduction | 7 | 2024 | 5226 | 0.390 |
Why?
| | Peptides | 2 | 2018 | 995 | 0.380 |
Why?
| | Metalloporphyrins | 1 | 2013 | 66 | 0.370 |
Why?
| | Oxidative Stress | 7 | 2025 | 1339 | 0.370 |
Why?
| | Mitochondria | 1 | 2019 | 984 | 0.360 |
Why?
| | Hemoglobins | 4 | 2017 | 384 | 0.360 |
Why?
| | Xanthine Oxidase | 1 | 2011 | 79 | 0.350 |
Why?
| | Inflammasomes | 1 | 2013 | 146 | 0.340 |
Why?
| | Animals, Newborn | 5 | 2022 | 902 | 0.340 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 173 | 0.330 |
Why?
| | Lipopolysaccharides | 4 | 2023 | 863 | 0.320 |
Why?
| | Extracellular Matrix | 2 | 2025 | 553 | 0.320 |
Why?
| | Cell Proliferation | 8 | 2022 | 2496 | 0.320 |
Why?
| | Male | 29 | 2026 | 72315 | 0.310 |
Why?
| | Up-Regulation | 2 | 2013 | 851 | 0.300 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2025 | 452 | 0.300 |
Why?
| | Carrier Proteins | 1 | 2013 | 737 | 0.290 |
Why?
| | Trachea | 1 | 2010 | 261 | 0.280 |
Why?
| | Sildenafil Citrate | 2 | 2018 | 60 | 0.270 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 675 | 0.270 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2018 | 139 | 0.260 |
Why?
| | Energy Metabolism | 2 | 2024 | 935 | 0.250 |
Why?
| | Rats, Sprague-Dawley | 10 | 2018 | 2527 | 0.240 |
Why?
| | Electron Spin Resonance Spectroscopy | 2 | 2023 | 97 | 0.240 |
Why?
| | Receptors, Interferon | 1 | 2026 | 60 | 0.240 |
Why?
| | Kidney | 3 | 2024 | 1495 | 0.230 |
Why?
| | Image Cytometry | 1 | 2025 | 12 | 0.230 |
Why?
| | Cells, Cultured | 6 | 2021 | 4154 | 0.230 |
Why?
| | Humans | 38 | 2026 | 144759 | 0.230 |
Why?
| | Serotonin | 2 | 2024 | 293 | 0.220 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2025 | 60 | 0.220 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2025 | 81 | 0.220 |
Why?
| | Acute Kidney Injury | 2 | 2024 | 865 | 0.220 |
Why?
| | Rats | 11 | 2018 | 5597 | 0.220 |
Why?
| | Platelet Factor 4 | 2 | 2025 | 36 | 0.220 |
Why?
| | Neutrophil Infiltration | 1 | 2025 | 104 | 0.220 |
Why?
| | Gene Expression Regulation | 5 | 2018 | 2608 | 0.210 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2024 | 24 | 0.210 |
Why?
| | Prolactin | 1 | 2024 | 89 | 0.210 |
Why?
| | Myofibroblasts | 3 | 2022 | 143 | 0.210 |
Why?
| | Nanoparticles | 2 | 2021 | 519 | 0.200 |
Why?
| | Hydroxylamine | 1 | 2023 | 7 | 0.200 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 198 | 0.200 |
Why?
| | Cellular Reprogramming | 1 | 2024 | 103 | 0.200 |
Why?
| | Nitric Oxide | 4 | 2018 | 897 | 0.200 |
Why?
| | Interleukin-1beta | 2 | 2018 | 395 | 0.200 |
Why?
| | Influenza A virus | 1 | 2024 | 113 | 0.200 |
Why?
| | NF-kappa B | 3 | 2018 | 661 | 0.200 |
Why?
| | Fibroblast Growth Factors | 1 | 2024 | 188 | 0.190 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2018 | 197 | 0.190 |
Why?
| | Uncoupling Protein 2 | 1 | 2022 | 9 | 0.190 |
Why?
| | Coinfection | 1 | 2024 | 141 | 0.190 |
Why?
| | Liver | 2 | 2024 | 1887 | 0.190 |
Why?
| | Hyaluronan Synthases | 1 | 2022 | 1 | 0.190 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2023 | 61 | 0.180 |
Why?
| | Wound Healing | 1 | 2025 | 351 | 0.180 |
Why?
| | Interleukin-10 | 1 | 2024 | 309 | 0.180 |
Why?
| | Glutathione | 1 | 2024 | 375 | 0.180 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2015 | 204 | 0.180 |
Why?
| | Adventitia | 2 | 2012 | 43 | 0.170 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2021 | 10 | 0.170 |
Why?
| | Succinate Dehydrogenase | 1 | 2021 | 57 | 0.170 |
Why?
| | Chemokine CCL5 | 1 | 2020 | 41 | 0.170 |
Why?
| | Alveolar Epithelial Cells | 2 | 2023 | 120 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2024 | 784 | 0.160 |
Why?
| | Cell Membrane Permeability | 2 | 2018 | 85 | 0.160 |
Why?
| | Placenta | 2 | 2024 | 780 | 0.160 |
Why?
| | Lung Diseases | 3 | 2017 | 787 | 0.150 |
Why?
| | Staphylococcal Infections | 1 | 2024 | 388 | 0.150 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 161 | 0.150 |
Why?
| | Hemodynamics | 4 | 2018 | 1121 | 0.150 |
Why?
| | Down Syndrome | 1 | 2026 | 534 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2017 | 636 | 0.150 |
Why?
| | Ephrin-A2 | 1 | 2018 | 4 | 0.150 |
Why?
| | Advisory Committees | 1 | 2020 | 228 | 0.140 |
Why?
| | Reperfusion Injury | 1 | 2022 | 300 | 0.140 |
Why?
| | Thrombocytopenia | 1 | 2020 | 205 | 0.140 |
Why?
| | Chronic Disease | 2 | 2017 | 1813 | 0.140 |
Why?
| | Glycocalyx | 1 | 2018 | 30 | 0.140 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.140 |
Why?
| | Mucociliary Clearance | 1 | 2018 | 43 | 0.140 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 39 | 0.140 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2018 | 108 | 0.140 |
Why?
| | Drug Repositioning | 1 | 2018 | 41 | 0.140 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 30 | 0.140 |
Why?
| | Ventricular Pressure | 2 | 2015 | 52 | 0.140 |
Why?
| | Glioma | 1 | 2022 | 425 | 0.130 |
Why?
| | Blood Pressure | 5 | 2022 | 1769 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 207 | 0.130 |
Why?
| | PPAR gamma | 1 | 2018 | 176 | 0.130 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2017 | 35 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 37 | 0.120 |
Why?
| | Caspase 1 | 2 | 2018 | 148 | 0.120 |
Why?
| | Arginine | 2 | 2014 | 262 | 0.120 |
Why?
| | rho-Associated Kinases | 2 | 2017 | 83 | 0.120 |
Why?
| | Heart Ventricles | 1 | 2021 | 760 | 0.120 |
Why?
| | Disease Progression | 3 | 2019 | 2847 | 0.110 |
Why?
| | MAP Kinase Signaling System | 2 | 2021 | 310 | 0.110 |
Why?
| | Ventricular Function, Right | 2 | 2015 | 297 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 85 | 0.110 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1253 | 0.110 |
Why?
| | Administration, Inhalation | 4 | 2018 | 574 | 0.110 |
Why?
| | Cholestasis | 1 | 2018 | 219 | 0.110 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 675 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 691 | 0.110 |
Why?
| | Haptoglobins | 1 | 2015 | 66 | 0.110 |
Why?
| | Pericytes | 1 | 2014 | 36 | 0.110 |
Why?
| | Anemia, Sickle Cell | 1 | 2018 | 312 | 0.100 |
Why?
| | Female | 12 | 2026 | 78271 | 0.100 |
Why?
| | Altitude | 1 | 2018 | 473 | 0.100 |
Why?
| | Hyperoxia | 1 | 1995 | 99 | 0.100 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2014 | 118 | 0.100 |
Why?
| | Fibroblasts | 4 | 2025 | 1034 | 0.100 |
Why?
| | Vascular Diseases | 2 | 2015 | 251 | 0.100 |
Why?
| | Alprostadil | 1 | 2013 | 29 | 0.100 |
Why?
| | Apoptosis | 4 | 2022 | 2430 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 635 | 0.100 |
Why?
| | I-kappa B Kinase | 1 | 2013 | 51 | 0.100 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 114 | 0.090 |
Why?
| | Lactic Acid | 3 | 2023 | 302 | 0.090 |
Why?
| | I-kappa B Proteins | 1 | 2013 | 74 | 0.090 |
Why?
| | Cerium | 2 | 2023 | 19 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 557 | 0.090 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 95 | 0.090 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2015 | 248 | 0.090 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2015 | 219 | 0.090 |
Why?
| | Protein Binding | 1 | 2018 | 2273 | 0.090 |
Why?
| | Altitude Sickness | 1 | 2013 | 141 | 0.090 |
Why?
| | Transcriptome | 1 | 2018 | 1045 | 0.090 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2013 | 169 | 0.090 |
Why?
| | Interleukin-18 | 1 | 2013 | 235 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2014 | 442 | 0.090 |
Why?
| | Catalase | 4 | 2015 | 130 | 0.090 |
Why?
| | Blood Vessels | 1 | 2012 | 171 | 0.090 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2011 | 52 | 0.080 |
Why?
| | Vasoconstrictor Agents | 2 | 2022 | 144 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1782 | 0.080 |
Why?
| | Transcriptional Activation | 1 | 2013 | 383 | 0.080 |
Why?
| | Drug Carriers | 3 | 2018 | 130 | 0.080 |
Why?
| | Phosphorylation | 1 | 2015 | 1732 | 0.080 |
Why?
| | Rats, Inbred WKY | 1 | 2010 | 37 | 0.080 |
Why?
| | Drug Administration Routes | 1 | 2010 | 42 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2194 | 0.080 |
Why?
| | Blood Circulation | 1 | 2010 | 44 | 0.080 |
Why?
| | Nitrosation | 1 | 2010 | 8 | 0.080 |
Why?
| | Stress, Physiological | 2 | 2012 | 453 | 0.080 |
Why?
| | Airway Remodeling | 1 | 2011 | 64 | 0.080 |
Why?
| | Accreditation | 1 | 2011 | 101 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3409 | 0.080 |
Why?
| | Microvessels | 1 | 2011 | 99 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2013 | 509 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2363 | 0.080 |
Why?
| | Tyrosine | 1 | 2010 | 222 | 0.080 |
Why?
| | Phenotype | 2 | 2015 | 3162 | 0.070 |
Why?
| | Models, Biological | 1 | 2017 | 1821 | 0.070 |
Why?
| | Vasoconstriction | 1 | 2010 | 217 | 0.070 |
Why?
| | Cattle | 1 | 2011 | 1000 | 0.070 |
Why?
| | Workload | 1 | 2011 | 170 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1387 | 0.070 |
Why?
| | Fetus | 1 | 2013 | 803 | 0.070 |
Why?
| | Gene Expression | 1 | 2013 | 1490 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 479 | 0.070 |
Why?
| | Porosity | 2 | 2018 | 96 | 0.060 |
Why?
| | Time Factors | 1 | 2018 | 7173 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2022 | 297 | 0.060 |
Why?
| | Sheep | 2 | 2022 | 880 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 969 | 0.060 |
Why?
| | Antioxidants | 3 | 2014 | 549 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 557 | 0.060 |
Why?
| | Polyglycolic Acid | 2 | 2017 | 44 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2024 | 3604 | 0.060 |
Why?
| | Sulfonamides | 2 | 2022 | 580 | 0.050 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 28 | 0.050 |
Why?
| | Critical Care | 1 | 2011 | 695 | 0.050 |
Why?
| | Schistosoma | 1 | 2024 | 28 | 0.050 |
Why?
| | Complement C5a | 1 | 2024 | 54 | 0.050 |
Why?
| | Complement C3a | 1 | 2024 | 40 | 0.050 |
Why?
| | Lipid Peroxidation | 2 | 2017 | 160 | 0.050 |
Why?
| | Schistosomiasis | 1 | 2024 | 49 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2010 | 1125 | 0.050 |
Why?
| | Maternal Behavior | 1 | 2024 | 84 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2024 | 148 | 0.050 |
Why?
| | Cell Line | 3 | 2015 | 2882 | 0.050 |
Why?
| | Orthomyxoviridae Infections | 1 | 2024 | 72 | 0.050 |
Why?
| | Vascular Resistance | 2 | 2015 | 367 | 0.050 |
Why?
| | Nitrogen Oxides | 1 | 2023 | 54 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2015 | 138 | 0.050 |
Why?
| | Phosphofructokinase-2 | 1 | 2022 | 16 | 0.050 |
Why?
| | Gene Deletion | 1 | 2024 | 389 | 0.050 |
Why?
| | Breath Tests | 1 | 2023 | 79 | 0.050 |
Why?
| | Spectrum Analysis | 1 | 2023 | 93 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1982 | 0.050 |
Why?
| | Creatinine | 1 | 2024 | 506 | 0.050 |
Why?
| | Lasers | 1 | 2023 | 132 | 0.050 |
Why?
| | Tryptophan Hydroxylase | 1 | 2022 | 54 | 0.050 |
Why?
| | Pediatrics | 1 | 2011 | 1114 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 339 | 0.050 |
Why?
| | Hydrogen Peroxide | 2 | 2012 | 336 | 0.040 |
Why?
| | Biomarkers | 2 | 2024 | 4271 | 0.040 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 87 | 0.040 |
Why?
| | 3' Untranslated Regions | 1 | 2022 | 152 | 0.040 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2022 | 132 | 0.040 |
Why?
| | Complement Activation | 1 | 2024 | 411 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2024 | 316 | 0.040 |
Why?
| | Angiotensin II | 1 | 2021 | 97 | 0.040 |
Why?
| | Ischemia | 1 | 2024 | 421 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 240 | 0.040 |
Why?
| | Metabolome | 1 | 2024 | 384 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2022 | 261 | 0.040 |
Why?
| | Pregnancy | 2 | 2024 | 7190 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2023 | 474 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 279 | 0.040 |
Why?
| | Internship and Residency | 1 | 2011 | 1257 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 4089 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 548 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2024 | 6429 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2021 | 243 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 108 | 0.040 |
Why?
| | Syndecans | 1 | 2018 | 5 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2018 | 59 | 0.040 |
Why?
| | Metabolomics | 1 | 2024 | 727 | 0.030 |
Why?
| | Caspases, Initiator | 1 | 2018 | 17 | 0.030 |
Why?
| | Amino Acid Oxidoreductases | 2 | 1995 | 19 | 0.030 |
Why?
| | Liver X Receptors | 1 | 2018 | 30 | 0.030 |
Why?
| | Endothelins | 1 | 2018 | 63 | 0.030 |
Why?
| | Drug Liberation | 1 | 2018 | 36 | 0.030 |
Why?
| | Information Dissemination | 1 | 2020 | 223 | 0.030 |
Why?
| | Influenza, Human | 1 | 2024 | 616 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1985 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2018 | 134 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2020 | 281 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 760 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1833 | 0.030 |
Why?
| | Needs Assessment | 1 | 2020 | 404 | 0.030 |
Why?
| | Drug Compounding | 1 | 2018 | 107 | 0.030 |
Why?
| | Nitric Oxide Synthase | 2 | 1995 | 235 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 213 | 0.030 |
Why?
| | Monocrotaline | 1 | 2017 | 32 | 0.030 |
Why?
| | Stem Cells | 2 | 2012 | 626 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 232 | 0.030 |
Why?
| | Polyethyleneimine | 1 | 2017 | 18 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 105 | 0.030 |
Why?
| | Hepatocytes | 1 | 2018 | 223 | 0.030 |
Why?
| | Lipoproteins | 1 | 2018 | 169 | 0.030 |
Why?
| | Rabbits | 2 | 1995 | 648 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 172 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1047 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2017 | 109 | 0.030 |
Why?
| | Microspheres | 1 | 2017 | 142 | 0.030 |
Why?
| | Hemolysis | 1 | 2018 | 243 | 0.030 |
Why?
| | Histones | 1 | 2022 | 669 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 209 | 0.030 |
Why?
| | Models, Animal | 1 | 2018 | 392 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 948 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 136 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 891 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 2061 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 410 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 2112 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1047 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1137 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 411 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1995 | 49 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1995 | 106 | 0.030 |
Why?
| | Free Radicals | 1 | 1995 | 110 | 0.030 |
Why?
| | Sepharose | 1 | 2014 | 32 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 847 | 0.030 |
Why?
| | Child | 2 | 2026 | 22633 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 246 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2022 | 3540 | 0.030 |
Why?
| | Platelet Activating Factor | 1 | 1994 | 49 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 178 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2015 | 184 | 0.020 |
Why?
| | Glycine | 1 | 2014 | 187 | 0.020 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 9 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2013 | 49 | 0.020 |
Why?
| | Permeability | 1 | 2013 | 168 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2013 | 56 | 0.020 |
Why?
| | Infant, Premature | 1 | 2017 | 611 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 115 | 0.020 |
Why?
| | Heparin | 1 | 2014 | 244 | 0.020 |
Why?
| | von Willebrand Factor | 1 | 2013 | 85 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 780 | 0.020 |
Why?
| | Vasa Vasorum | 1 | 2012 | 37 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2012 | 33 | 0.020 |
Why?
| | Drug Stability | 1 | 2013 | 164 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 132 | 0.020 |
Why?
| | Infusion Pumps | 1 | 2012 | 32 | 0.020 |
Why?
| | Spin Labels | 1 | 2012 | 59 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 145 | 0.020 |
Why?
| | Iron | 1 | 2015 | 359 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 183 | 0.020 |
Why?
| | Aerosols | 1 | 2013 | 186 | 0.020 |
Why?
| | Cardiac Output | 1 | 2012 | 179 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1694 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5960 | 0.020 |
Why?
| | Receptor, TIE-2 | 1 | 2011 | 11 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1289 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 276 | 0.020 |
Why?
| | Cerebellum | 1 | 2013 | 223 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 824 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 406 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 142 | 0.020 |
Why?
| | Vasculitis | 1 | 2011 | 69 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4564 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7990 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1187 | 0.020 |
Why?
| | Oxygen | 1 | 1995 | 995 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1098 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 523 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1054 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2832 | 0.020 |
Why?
| | Thrombosis | 1 | 2011 | 393 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1257 | 0.020 |
Why?
| | Genes | 1 | 1986 | 226 | 0.020 |
Why?
| | Infant | 1 | 2017 | 10034 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 11679 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2011 | 2050 | 0.010 |
Why?
| | Adult | 1 | 2026 | 40449 | 0.010 |
Why?
| | Aged | 1 | 2022 | 25913 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1986 | 1496 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 10779 | 0.010 |
Why?
| | Ditiocarb | 1 | 1994 | 3 | 0.010 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1994 | 9 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1994 | 10 | 0.010 |
Why?
| | Epoprostenol | 1 | 1994 | 131 | 0.010 |
Why?
| | United States | 1 | 2011 | 15966 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 250 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1994 | 1047 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1986 | 321 | 0.000 |
Why?
| | Molecular Weight | 1 | 1986 | 327 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1986 | 327 | 0.000 |
Why?
| | Aging | 1 | 1986 | 1966 | 0.000 |
Why?
|
|
Nozik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|